-
Data presented at the AIDS 2014 international conference indicates that oral HIV pre-exposure prophylaxis (PrEP) provides a high degree of protection against HIV infection, even for individuals who miss some daily doses.
-
Science is looking at a wireless microchip implant, with remote drug delivery control, that is designed to last up to 16 years.
-
Presentations at the AIDS 2014 conference offer differing outlooks on increased risk of HIV in women using contraceptive injections.
-
Long-acting reversible contraception (LARC) — the copper T and levonorgestrel intrauterine devices (IUDs) and the birth control implant — are the most effective reversible methods available to prevent unintended pregnancy. They last for several years and are easy to use. Clinicians can draw lessons from the Contraceptive CHOICE project in St. Louis on how to make their clinics "LARC First.
-
Placenta accreta can represent a real clinical conundrum, especially if it is unrecognized before delivery.
-
A few studies have suggested that we tend to underestimate blood loss during deliveries and cesarean sections. A group from Louisiana State University has addressed this issue again in a very clever way.
-
-
Curtis and colleagues from the University of Alabama at Birmingham measured the rate of hip fracture among women who discontinued bisphosphonate therapy compared with women who remained on treatment.
-
The Women's Iinternational Study of Long Duration Oestrogen after the Menopause (WISDOM) trial was a randomized, controlled trial in the United Kingdom, Australia, and New Zealand, of 3721 women aged 50-69 treated with either combined 0.625 mg conjugated estrogens and 2.5/5.0 mg medroxyprogesterone, or placebo. The original plan was to randomize 22,300 women to the study that would last 10 years.
-
One of the most common and poignant questions an ovarian cancer patient asks upon learning of her diagnosis is, "How did I get this?
